• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

选择性变构代谢型谷氨酸受体1拮抗剂的虚拟筛选及香豆素衍生物的构效关系研究

Virtual screening for selective allosteric mGluR1 antagonists and structure-activity relationship investigations for coumarine derivatives.

作者信息

Noeske Tobias, Jirgensons Aigars, Starchenkovs Igors, Renner Steffen, Jaunzeme Ieva, Trifanova Dina, Hechenberger Mirko, Bauer Tanja, Kauss Valerjans, Parsons Christopher G, Schneider Gisbert, Weil Tanja

机构信息

Merz Pharmaceuticals GmbH, Altenhöfer Allee 3, 60438 Frankfurt am Main, Germany.

出版信息

ChemMedChem. 2007 Dec;2(12):1763-73. doi: 10.1002/cmdc.200700151.

DOI:10.1002/cmdc.200700151
PMID:17868161
Abstract

A virtual screening study towards novel noncompetitive antagonists of the metabotropic glutamate receptor 1 (mGluR1) is described. Alignment-free topological pharmacophore descriptors (CATS) were used to encode the screening compounds. All virtual hits were characterized with respect to their allosteric antagonistic effect on mGluR1 in both functional and binding assays. Exceptionally high hit rates of up to 26 % were achieved, confirming the applicability of this virtual screening concept. Most of the compounds were found to be moderately active, however, one potent and subtype selective mGluR1 antagonist, 13 (IC(50): 0.362 microM, SEM +/-0.031; K(i): 0.753 microM, SEM +/-0.048), based on a coumarine scaffold was discovered. In a following activity optimization program a series of coumarine derivatives was synthesized. This led to the discovery of potent (60, IC(50): 0.058 microM, SEM +/-0.008; K(i): 0.293 microM, SEM +/-0.022) and subtype selective (rmGluR5 IC(50): 28.6 microM) mGluR1 antagonists. From our homology model of mGluR1 we derived a potential binding mode within the allosteric transmembrane region. Potential interacting patterns are proposed considering the difference of the binding pockets between rat and human receptors. The study demonstrates the applicability of ligand-based virtual screening for noncompetitive antagonists of a G-protein coupled receptor, resulting in novel, potent, and selective agents.

摘要

本文描述了一项针对代谢型谷氨酸受体1(mGluR1)新型非竞争性拮抗剂的虚拟筛选研究。使用无比对拓扑药效团描述符(CATS)对筛选化合物进行编码。所有虚拟命中化合物均通过功能和结合试验,对其对mGluR1的变构拮抗作用进行了表征。获得了高达26%的异常高命中率,证实了这种虚拟筛选概念的适用性。发现大多数化合物活性适中,然而,基于香豆素骨架发现了一种强效且亚型选择性的mGluR1拮抗剂13(IC(50):0.362 microM,标准误±0.031;K(i):0.753 microM,标准误±0.048)。在随后的活性优化计划中,合成了一系列香豆素衍生物。这导致发现了强效(60,IC(50):0.058 microM,标准误±0.008;K(i):0.293 microM,标准误±0.022)且亚型选择性(rmGluR5 IC(50):28.6 microM)的mGluR1拮抗剂。从我们的mGluR1同源模型中,我们推导了变构跨膜区域内的潜在结合模式。考虑到大鼠和人类受体结合口袋的差异,提出了潜在的相互作用模式。该研究证明了基于配体的虚拟筛选对于G蛋白偶联受体非竞争性拮抗剂的适用性,从而产生了新型、强效和选择性的药物。

相似文献

1
Virtual screening for selective allosteric mGluR1 antagonists and structure-activity relationship investigations for coumarine derivatives.选择性变构代谢型谷氨酸受体1拮抗剂的虚拟筛选及香豆素衍生物的构效关系研究
ChemMedChem. 2007 Dec;2(12):1763-73. doi: 10.1002/cmdc.200700151.
2
Synergism of virtual screening and medicinal chemistry: identification and optimization of allosteric antagonists of metabotropic glutamate receptor 1.虚拟筛选与药物化学的协同作用:代谢型谷氨酸受体1变构拮抗剂的鉴定与优化
Bioorg Med Chem. 2009 Aug 1;17(15):5708-15. doi: 10.1016/j.bmc.2009.05.072. Epub 2009 Jun 23.
3
Structure-activity relationship of triazafluorenone derivatives as potent and selective mGluR1 antagonists.作为强效和选择性代谢型谷氨酸受体1拮抗剂的三氮杂芴酮衍生物的构效关系
J Med Chem. 2005 Nov 17;48(23):7374-88. doi: 10.1021/jm0504407.
4
Positive and negative modulation of group I metabotropic glutamate receptors.I型代谢型谷氨酸受体的正向和负向调节
J Med Chem. 2008 Feb 14;51(3):634-47. doi: 10.1021/jm0611298. Epub 2008 Jan 4.
5
Radioligand binding properties and pharmacological characterization of 6-amino-N-cyclohexyl-N,3-dimethylthiazolo[3,2-a]benzimidazole-2-carboxamide (YM-298198), a high-affinity, selective, and noncompetitive antagonist of metabotropic glutamate receptor type 1.6-氨基-N-环己基-N,3-二甲基噻唑并[3,2-a]苯并咪唑-2-甲酰胺(YM-298198)的放射性配体结合特性及药理学特征,一种代谢型谷氨酸受体1的高亲和力、选择性和非竞争性拮抗剂
J Pharmacol Exp Ther. 2005 Oct;315(1):163-9. doi: 10.1124/jpet.105.087171. Epub 2005 Jun 23.
6
Unique antipsychotic activities of the selective metabotropic glutamate receptor 1 allosteric antagonist 2-cyclopropyl-5-[1-(2-fluoro-3-pyridinyl)-5-methyl-1H-1,2,3-triazol-4-yl]-2,3-dihydro-1H-isoindol-1-one.选择性代谢型谷氨酸受体1变构拮抗剂2-环丙基-5-[1-(2-氟-3-吡啶基)-5-甲基-1H-1,2,3-三唑-4-基]-2,3-二氢-1H-异吲哚-1-酮的独特抗精神病活性
J Pharmacol Exp Ther. 2009 Jul;330(1):179-90. doi: 10.1124/jpet.109.151118. Epub 2009 Apr 9.
7
Identification of a novel transmembrane domain involved in the negative modulation of mGluR1 using a newly discovered allosteric mGluR1 antagonist, 3-cyclohexyl-5-fluoro-6-methyl-7-(2-morpholin-4-ylethoxy)-4H-chromen-4-one.利用新发现的变构代谢型谷氨酸受体1(mGluR1)拮抗剂3-环己基-5-氟-6-甲基-7-(2-吗啉-4-基乙氧基)-4H-色烯-4-酮鉴定参与mGluR1负调控的新型跨膜结构域
Neuropharmacology. 2009 Sep;57(4):438-45. doi: 10.1016/j.neuropharm.2009.06.017. Epub 2009 Jun 24.
8
Pharmacological characterization of a new, orally active and potent allosteric metabotropic glutamate receptor 1 antagonist, 4-[1-(2-fluoropyridin-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl-N-methyl-3,6-dihydropyridine-1(2H)-carboxamide (FTIDC).新型口服活性强效变构代谢型谷氨酸受体1拮抗剂4-[1-(2-氟吡啶-3-基)-5-甲基-1H-1,2,3-三唑-4-基]-N-异丙基-N-甲基-3,6-二氢吡啶-1(2H)-甲酰胺(FTIDC)的药理学特性
J Pharmacol Exp Ther. 2007 Jun;321(3):1144-53. doi: 10.1124/jpet.106.116574. Epub 2007 Mar 14.
9
In vitro and in vivo SAR of pyrido[3,4-d]pyramid-4-ylamine based mGluR1 antagonists.
Bioorg Med Chem Lett. 2009 Apr 15;19(8):2190-4. doi: 10.1016/j.bmcl.2009.02.106. Epub 2009 Mar 3.
10
A family of highly selective allosteric modulators of the metabotropic glutamate receptor subtype 5.亲代谢型谷氨酸受体5的一类高选择性变构调节剂。
Mol Pharmacol. 2003 Sep;64(3):731-40. doi: 10.1124/mol.64.3.731.

引用本文的文献

1
Computational Chemistry for the Identification of Lead Compounds for Radiotracer Development.用于放射性示踪剂开发的先导化合物鉴定的计算化学
Pharmaceuticals (Basel). 2023 Feb 18;16(2):317. doi: 10.3390/ph16020317.
2
Computational Drug Design Applied to the Study of Metabotropic Glutamate Receptors.计算药物设计在代谢型谷氨酸受体研究中的应用。
Molecules. 2019 Mar 20;24(6):1098. doi: 10.3390/molecules24061098.
3
In Silico Studies in Drug Research Against Neurodegenerative Diseases.计算机药物研究在神经退行性疾病防治中的应用
Curr Neuropharmacol. 2018;16(6):664-725. doi: 10.2174/1570159X15666170823095628.
4
Virtual Screening and Molecular Dynamics Study of Potential Negative Allosteric Modulators of mGluR1 from Chinese Herbs.基于中药的代谢型谷氨酸受体1潜在负性变构调节剂的虚拟筛选与分子动力学研究
Molecules. 2015 Jul 15;20(7):12769-86. doi: 10.3390/molecules200712769.
5
Computational Advances for the Development of Allosteric Modulators and Bitopic Ligands in G Protein-Coupled Receptors.G蛋白偶联受体变构调节剂和双位点配体开发中的计算进展
AAPS J. 2015 Sep;17(5):1080-95. doi: 10.1208/s12248-015-9776-y. Epub 2015 May 5.
6
Bayesian models for screening and TB Mobile for target inference with Mycobacterium tuberculosis.贝叶斯模型用于筛查,TB Mobile 用于结核分枝杆菌的靶标推断。
Tuberculosis (Edinb). 2014 Mar;94(2):162-9. doi: 10.1016/j.tube.2013.12.001. Epub 2013 Dec 19.
7
Computational methods in drug discovery.药物发现中的计算方法。
Pharmacol Rev. 2013 Dec 31;66(1):334-95. doi: 10.1124/pr.112.007336. Print 2014.
8
Chemically Advanced Template Search (CATS) for Scaffold-Hopping and Prospective Target Prediction for 'Orphan' Molecules.用于骨架跳跃和“孤儿”分子潜在靶点预测的化学高级模板搜索(CATS)
Mol Inform. 2013 Feb;32(2):133-138. doi: 10.1002/minf.201200141. Epub 2013 Feb 7.
9
Recent advances in the medicinal chemistry of the metabotropic glutamate receptor 1 (mGlu₁).代谢型谷氨酸受体 1(mGlu₁)的药物化学研究进展。
ACS Chem Neurosci. 2011 Aug 17;2(8):394-401. doi: 10.1021/cn2000124. Epub 2011 Mar 10.
10
Discovery of 2-(2-benzoxazoyl amino)-4-aryl-5-cyanopyrimidine as negative allosteric modulators (NAMs) of metabotropic glutamate receptor 5 (mGlu₅): from an artificial neural network virtual screen to an in vivo tool compound.2-(2-苯并恶唑基氨基)-4-芳基-5-氰基嘧啶作为代谢型谷氨酸受体5(mGlu₅)的负变构调节剂(NAMs)的发现:从人工神经网络虚拟筛选到体内工具化合物
ChemMedChem. 2012 Mar 5;7(3):406-14. doi: 10.1002/cmdc.201100510. Epub 2012 Jan 20.